Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Other Investing Activities
Investing cash flows not reported separately.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Other Investing Activities · Q1 FY2026 · quarter ended Mar 2026
Other investing activities outflow grows to $0
Q1 FY2026 other investing activities was $0, compared with $0 a year earlier. Trailing-twelve-month other investing activities was $0.
Context
- Other investing activities increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other investing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Investing Activities history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Investing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Investing Activities vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's LTM Mar 2026 other investing activities of $0 is the 6th largest of the 11 companies compared; the peer median is $5.5K.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $99.52M | — | — | 58.6% | |
| LTM Mar 2026 | $299.5K | +200.2% | — | 59.9% | |
| LTM Mar 2026 | $223K | +123.0% | — | — | |
| LTM Mar 2026 | $119K | — | — | 0.2% | |
| LTM Mar 2026 | $11K | -86.3% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | +100.0% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding NVCT) | $5.5K | +111.5% | — | 0.1% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.89M | 1.71M | 4.71M | 4.86M | 1.35M |
| Change in Working Capital | 1.49M | 3.82M | 1.74M | 1.9M | 4.4M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 1.85M | (139K) | (273K) | 3.78M |
| Other Working Capital | 1.49M | 1.97M | 1.88M | 2.17M | 625K |
| Other Non-Cash Items | 0 | 0 | (139K) | 0 | 4.68M |
| Operating Cash Flow | (9.5M) | (13.56M) | (15.95M) | (12.25M) | (16.01M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 15.25M | 31.88M | 5.29M | 12.04M | 29.11M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (4.07M) | 9.8M | (382K) | 0 |
| Financing Cash Flow | 15.25M | 27.81M | 15.09M | 11.65M | 29.11M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.74M | 14.25M | (867K) | (593K) | 13.1M |
| Free Cash Flow | (9.5M) | (13.56M) | (15.95M) | (12.25M) | (16.01M) |
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.